SpyGlass Pharma

IPO

Sustained Drug Delivery

Public · Aliso Viejo, United States · Founded 2019 · $199.2M raised

Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$199.2M
Last Round
$75.0M Series DJun 2025
Rounds
5
Type
Public

About

SpyGlass Pharma is a late-stage biopharmaceutical company developing implantable ophthalmic drug delivery systems for patients with glaucoma and ocular hypertension. Its BIM-IOL System delivers sustained-release bimatoprost from an intraocular lens implanted during routine cataract surgery, aiming to eliminate lifelong eye drop dependence. The company went public on Nasdaq (SGP) in February 2026.

Summary

SpyGlass Pharma is a Biotech company based in Aliso Viejo, United States, founded in 2019. It has raised $199.2M in total across 5 rounds, most recently a $75.0M Series D round in Jun 2025. Investors include RA Capital Management, Sands Capital and Gilde Healthcare.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOFeb 2026
$150.0M

Sign up to see all 6 rounds

Seed through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SpyGlass Pharma on Indexed.vc
<a href="https://indexed.vc/companies/spyglass-pharma"><img src="https://indexed.vc/api/badge/company/spyglass-pharma" alt="SpyGlass Pharma on Indexed.vc" width="260" height="76" /></a>